💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Concord Drugs Limited is an India-based pharmaceutical company. The Company's principal activity is to manufacture licensed drugs based on the formulations approved. The Company is focused on developing drug delivery systems, including multiple unit pellet system (MUPS),…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, stagnant business, reasonably priced — but flagged on governance.
Concord Drugs Limited is scored on the pharma / healthcare framework. It keeps a thin 1.4% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT -5.42×) — worth a closer look. Free cash flow is worth about -7.3% of its market value.
Over the last 3 years revenue compounded at 15%/yr and profit at 2%/yr. Book value itself has compounded 15%/yr — the hallmark of a genuine compounder. Return on equity is a weak 2.2%. In the latest quarter profit grew 109% versus the prior quarter.
At 75× earnings, the stock sits at the 37th percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price already implies ~20%/yr earnings growth sustained for a decade — a demanding bar. The forensic screen raises a red flag: Only ₹0.15 of cash per ₹1 profit over 4 years — earnings not converting to cash.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 45.62 | — | — |
| P/B | 2.01 | 4.11 | better |
| EV/EBITDA | 18.52 | 19.15 | better |
| ROE | 2.17 | 0.68 | better |
| ROCE | 5.12 | 6.87 | worse |
| ROA | 2.74 | 1.26 | better |
| Quick Ratio | 1.32 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
15% CAGR over 3 years — steady double-digit compounder. Growth is accelerating — latest year outpaced the prior year's rate.
Revenue is outpacing profit (15% vs 2%) — costs are rising faster than the top line. The latest year saw a +212% swing — check if it's a one-off or structural.
Operating margins have been stable around 2% — no major structural shift.
ROE at 2% — modest; the capital isn't working hard. Low variance across years — a predictable business that earns steadily on its equity base.
Profit grew faster than EPS (2% vs -4%) — share dilution is eroding per-share value. -4% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
1 of 4 years had negative operating cash flow — profitability on paper may not translate to cash. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 45% QoQ — could be seasonality or a genuine slowdown. Wide quarterly swings (73% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate stepping up — recent quarters average 116% above earlier ones.
Profit jumped 109% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (2% → 5%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 45.1% — dispersed ownership; institutional flows drive the stock. Promoters reduced 9.3pp over 4 quarters — watch whether this is planned divestment or pledge invocations.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.